Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.45 |
| ▸ | BRS3 | P32247 | 6/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.44 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863125 | 0.86 | CYP4F2 (0.45) | PTGER1PTGER4PTGER3PTGER2ALDH1A1 | |
| SCHEMBL5863181 | 0.86 | SMN1; SMN2 (0.47) | PTGER1PTGER4PTGER3PTGER2ALDH1A1 | |
| SCHEMBL5863142 | 0.83 | PKM (0.58) | — | |
| SCHEMBL5863144 | 0.82 | ALDH1A1 (0.49) | PTGER1PTGER4PTGER3PTGER2ALDH1A1 | |
| Oxalic Acid SCHEMBL5863493 | 0.79 | KDM4E (0.45) | ALDH1A1BCL2L1 | |
| SCHEMBL5863052 | 0.79 | KDM4E (0.45) | ALDH1A1 | |
| SCHEMBL5863173 | 0.78 | MRGPRX4 (0.53) | PDE7APDE7BBCL2L1 | |
| Oxalic Acid SCHEMBL5863081 | 0.77 | KDM4E (0.44) | ALDH1A1 | |
| SCHEMBL5863071 | 0.77 | PKM (0.54) | PTGER1PTGER4PTGER3PTGER2ALDH1A1 | |
| SCHEMBL5639196 | 0.77 | ALDH1A1 (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132456-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2006-11-07 | — | — | US | claimed |
| US-20060052449-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | claimed |
| EP-1572637-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-14 | — | — | EP | claimed |
| WO-2004052848-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | claimed |
| US-7132456-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060052449-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | disclosed |
| EP-1572637-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052848-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052449-A1 | Novel mch receptor antagonists | MCHR1, MCHR2, MC1R | PTGER1 845/4885PTGER4 2367/4885PTGER3 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.